2-(Pyrimidin-4-ylamino)-thiazole-5-carbonitrile | 436852-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(Pyrimidin-4-ylamino)-thiazole-5-carbonitrile
• 英文别名: 2-(Pyrimidin-4-ylamino)thiazole-5-carbonitrile；2-(pyrimidin-4-ylamino)-1,3-thiazole-5-carbonitrile
• CAS: 436852-19-6
• 化学式: C₈H₅N₅S
• 分子量: 203.227
• InChiKey: SMNGUXOKYVUIRA-UHFFFAOYSA-N

物化性质

• 沸点：
  429.3±43.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氨基嘧啶 、 2-氯-5-氰基噻唑 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-(Pyrimidin-4-ylamino)-thiazole-5-carbonitrile
  参考文献：
  名称：

  Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase

  摘要：

  Pyrimidino-thiazolyl carbonitriles were prepared that are potent VEGFR-2 (KDR) kinase inhibitors. The modification of lead structures resulted in 3m which exhibited the best overall profile in KDR inhibitory activity, iv/po pharmacokinetics, and reduced hERG affinity. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.089

文献信息

• Tyrosine kinase inhibitors
  申请人：——

  公开号：US20020137755A1

  公开（公告）日：2002-09-26

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调控酪氨酸激酶信号传导的化合物，含有这些化合物的组合物，以及使用它们治疗依赖于酪氨酸激酶的疾病和病况的方法，如在哺乳动物中的血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE-KINASE
  申请人：MERCK & CO INC

  公开号：WO2002045652A2

  公开（公告）日：2002-06-13

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号转导的化合物，包含这些化合物的组合物以及使用它们治疗哺乳动物的酪氨酸激酶依赖性疾病和病况的方法，例如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病性视网膜病变、炎症性疾病等。
• TYROSINE KINASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1341540A2

  公开（公告）日：2003-09-10
• US7115597B2
  申请人：——

  公开号：US7115597B2

  公开（公告）日：2006-10-03
• Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase
  作者：John T. Sisko、Thomas J. Tucker、Mark T. Bilodeau、Carolyn A. Buser、Patrice A. Ciecko、Kathleen E. Coll、Christine Fernandes、Jackson B. Gibbs、Timothy J. Koester、Nancy Kohl、Joseph J. Lynch、Xianzhi Mao、Debra McLoughlin、Cynthia M. Miller-Stein、Leonard D. Rodman、Keith W. Rickert、Laura Sepp-Lorenzino、Jennifer M. Shipman、Kenneth A. Thomas、Bradley K. Wong、George D. Hartman

  DOI：10.1016/j.bmcl.2005.11.089

  日期：2006.3

  Pyrimidino-thiazolyl carbonitriles were prepared that are potent VEGFR-2 (KDR) kinase inhibitors. The modification of lead structures resulted in 3m which exhibited the best overall profile in KDR inhibitory activity, iv/po pharmacokinetics, and reduced hERG affinity. (C) 2005 Elsevier Ltd. All rights reserved.